Dizal Pharma announced that its experimental cancer medicine Sunvozertide has received U.S. Food and Drug Administration (FDA) approval through a fast‑track review. The drug targets a rare genetic mutation (EGFR exon20 insertion) that drives a tough‑to‑treat form of non‑small cell lung cancer. This marks the first time a Chinese‑developed, novel therapy has cleared the FDA’s rigorous standards for this patient group. The approval was based on strong results from the international, multi‑center trial WU‑KONG1B, which showed Sunvozertide can shrink tumors and extend survival in patients who have already tried other treatments. Building on that success, researchers have now presented early data from a Phase 3 study (WU‑KONG28) that explores using Sunvozertide as the initial therapy for newly diagnosed patients. Those findings were shared at the 2026 American Society of Clinical Oncology (ASCO) meeting and published in the New England Journal of Medicine. Dizal Pharma has filed marketing applications with both China’s National Medical Products Administration and the FDA to expand Sunvozertide’s label to first‑line treatment. Both regulators have previously granted the drug breakthrough therapy status, underscoring its potential to change the outlook for lung‑cancer patients with this rare mutation.
Read more